IL4R and neoplasm: This notion has been demonstrated for the chimeric cytokine receptor IL-4R–IL-7R, which comprises the anti-inflammatory IL-4 receptor (IL-4R) exodomain fused to the pro-inflammatory IL-7 receptor (IL-7R) endodomain.116 Upon receptor engagement by tumour-derived IL-4, immunosuppressive effects were abrogated, increasing proliferation and activation of tumour-directed cytotoxic T cells and enhancing the anti-tumour activity in vivo.